Johnson & Johnson
JNJ- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000200406
In the last 90 days, Johnson & Johnson insiders filed 0 open-market purchases and 6 sales; 4,699 institutions reported holding it in 13F filings for Q2 2026, worth $456.9B in total; 5 superinvestors hold it, including Markel Group and Fairfax Financial.
Holders of 5% or more of JNJ
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Johnson & Johnson, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Johnson & Johnson on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
2 Schedule 13D and 13G filings on Johnson & Johnson, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 1, 20268:39 AM ET | Vanguard Capital Management LLC | 13G | 7.49%180.6M shares | New | Mar 31, 2026 | SEC |
| Mar 26, 202610:05 AM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −10.10 ppfrom 10.10%Below 5% | Mar 13, 2026 | SEC |
| Feb 5, 202612:23 PM ET | Vanguard Group Inc | 13G/A | 10.10%243.5M shares | – | Jan 30, 2026 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Johnson & Johnson shares.
No Form 144 notices for Johnson & Johnson are on file.